Freedom Broker has increased its price target for Pfizer Inc. to $34 from $33, while reiterating a Buy rating. This adjustment suggests a potential upside of 15.7% from the stock's closing price on November 6, 2026, indicating a moderately positive outlook from the analyst.
Freedom Broker, an analyst firm, has raised its price target for Pfizer (PFE) to $34, up from $33, and maintained a 'Buy' rating. This indicates a continued positive sentiment from the analyst regarding Pfizer's future performance. The 15.7% implied upside from the November 6, 2026 closing price suggests that the analyst believes the stock has significant room for growth. This news is generally positive for current Pfizer shareholders and could attract new investors, potentially leading to a short-term bump in the stock price. However, as it's an analyst's opinion, its long-term impact depends on Pfizer's actual financial performance and market conditions.